NURIX THERAPEUTICS INC (NRIX) Stock Price & Overview
NASDAQ:NRIX • US67080M1036
Current stock price
The current stock price of NRIX is 16.3 USD. Today NRIX is up by 2.45%. In the past month the price increased by 5.98%. In the past year, price increased by 59.18%.
NRIX Key Statistics
- Market Cap
- 1.686B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.04
- Dividend Yield
- N/A
NRIX Stock Performance
NRIX Stock Chart
NRIX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NRIX. When comparing the yearly performance of all stocks, NRIX is one of the better performing stocks in the market, outperforming 75.79% of all stocks.
NRIX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NRIX. No worries on liquidiy or solvency for NRIX as it has an excellent financial health rating, but there are worries on the profitability.
NRIX Earnings
NRIX Forecast & Estimates
23 analysts have analysed NRIX and the average price target is 30.98 USD. This implies a price increase of 90.08% is expected in the next year compared to the current price of 16.3.
For the next year, analysts expect an EPS growth of -2.29% and a revenue growth -26.71% for NRIX
NRIX Groups
Sector & Classification
NRIX Financial Highlights
Over the last trailing twelve months NRIX reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.42% | ||
| ROE | -61.4% | ||
| Debt/Equity | 0 |
NRIX Ownership
NRIX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NRIX
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Company Info
IPO: 2020-07-24
NURIX THERAPEUTICS INC
1600 Sierra Point Pkwy
Brisbane California CALIFORNIA 94158 US
CEO: Arthur T. Sands
Employees: 317
Phone: 14156605320
NURIX THERAPEUTICS INC / NRIX FAQ
What does NURIX THERAPEUTICS INC do?
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
What is the stock price of NURIX THERAPEUTICS INC today?
The current stock price of NRIX is 16.3 USD. The price increased by 2.45% in the last trading session.
What is the dividend status of NURIX THERAPEUTICS INC?
NRIX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NRIX stock?
NRIX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for NRIX stock?
NURIX THERAPEUTICS INC (NRIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
What is the expected growth for NRIX stock?
The Revenue of NURIX THERAPEUTICS INC (NRIX) is expected to decline by -26.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does NURIX THERAPEUTICS INC have?
NURIX THERAPEUTICS INC (NRIX) currently has 317 employees.